about
Expected and unexpected features of protein-binding RNA aptamersEx Vivo and In Vivo Imaging and Biodistribution of Aptamers Targeting the Human Matrix MetalloProtease-9 in MelanomasTargeting Insulin Receptor with a Novel Internalizing AptamerStructural computational modeling of RNA aptamersSelection and Characterization of an α6β4 Integrin blocking DNA AptamerOligonucleotide aptamers: A next-generation technology for the capture and detection of circulating tumor cells.A specific aptamer-cell penetrating peptides complex delivered siRNA efficiently and suppressed prostate tumor growth in vivo.Targeted Magnetic Nanotheranostics of Cancer.Synthetic Nucleic Acid Analogues in Gene Therapy: An Update for Peptide-Oligonucleotide Conjugates.Incorporation of aptamers in the terminal loop of shRNAs yields an effective and novel combinatorial targeting strategy.Nucleic Acid Aptamers: Emerging Applications in Medical Imaging, Nanotechnology, Neurosciences, and Drug Delivery.Size dependent targeted delivery of gold nanoparticles modified with the IL-6R-specific aptamer AIR-3A to IL-6R-carrying cells.Charomers-Interleukin-6 Receptor Specific Aptamers for Cellular Internalization and Targeted Drug Delivery.Integrin Inhibitors in Prostate Cancer.A novel nanomissile targeting two biomarkers and accurately bombing CTCs with doxorubicin.Selection and Identification of Skeletal-Muscle-Targeted RNA Aptamers.Design and Preparation of Aptamer-siRNA Chimeras (AsiCs) for Targeted Cancer Therapy.Aptamer-siRNA Chimeras: Discovery, Progress, and Future Prospects.
P2860
Q26750235-0C4EE46A-0406-4ABD-86B0-E45153BC5F1FQ28550308-48398EE8-3E66-4FD4-94AC-6275089E6F72Q28822291-154E3077-3900-425B-AEEC-BF884E3D2F03Q28828891-E006B0CB-24DE-447F-B737-430A24BBA7FFQ35957819-36A00D8E-73DA-4A8C-ABC2-D27E15DA30B7Q36689755-FC63FA00-EABC-4651-BFDF-808C732080E1Q37013316-00514465-9DA8-47FE-AE7E-B366B4387774Q39366606-377F76C6-DBC4-4B0B-8095-C296E70082F2Q39373677-94EF2DAA-EE14-48C6-8280-44F38A1CF0FDQ45873648-7C3D968D-D288-4F8F-9C8A-76206EE2BDF8Q47104247-925D5702-DDCC-4FCE-9B61-1E4D659BB98FQ47187038-BAEA1D17-C8AD-49AF-B339-102A409B1EACQ47324426-50C41AA4-7F53-4A1C-918B-90BCBB2C2E93Q50132111-71EB4D38-5B43-400E-9241-6833707DFEF5Q50656099-CB24E25D-1B6C-4054-9779-C8875C6AAC36Q52676614-5DCA60AD-1AD8-4F0F-8C57-991CB9C032A2Q53150917-C6F56EA9-7C5E-495C-8AE1-B3DB944ABF96Q55036897-D03BEFE1-B6E7-4297-8A4F-C85A7B484870
P2860
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Aptamers as drug delivery vehicles.
@en
type
label
Aptamers as drug delivery vehicles.
@en
prefLabel
Aptamers as drug delivery vehicles.
@en
P2093
P2860
P356
P1433
P1476
Aptamers as drug delivery vehicles
@en
P2093
Florian Mittelberger
Kristina Szameit
Sven Kruspe
P2860
P304
P356
10.1002/CMDC.201402163
P50
P577
2014-08-11T00:00:00Z